Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (70) 70
humans (69) 69
transplantation (69) 69
index medicus (61) 61
adult (54) 54
male (54) 54
female (52) 52
middle aged (52) 52
immunology (40) 40
aged (39) 39
hematology, oncology and palliative medicine (39) 39
hematopoietic stem cells (33) 33
disease-free survival (28) 28
stem cells (27) 27
bone marrow (25) 25
article (24) 24
bone-marrow-transplantation (24) 24
recurrence (24) 24
treatment outcome (24) 24
hematopoietic stem cell transplantation - methods (23) 23
adolescent (21) 21
chemotherapy (20) 20
retrospective studies (20) 20
transplantation, homologous (20) 20
cancer (19) 19
oncology (19) 19
versus-host-disease (19) 19
hematopoietic stem cell transplantation (18) 18
analysis (17) 17
survival (17) 17
young adult (17) 17
hematologic malignancies (16) 16
stem-cell transplantation (16) 16
transplantation, autologous (16) 16
leukemia (15) 15
transplantation conditioning - methods (15) 15
acute myeloid-leukemia (14) 14
mortality (14) 14
survival analysis (14) 14
cyclophosphamide (13) 13
survival rate (13) 13
blood (11) 11
hematopoietic stem cell transplantation - mortality (11) 11
multiple myeloma (11) 11
therapy (11) 11
tissue donors (11) 11
care and treatment (10) 10
graft vs host disease - prevention & control (10) 10
hematologic neoplasms - therapy (10) 10
hematopoietic stem cell transplantation - adverse effects (10) 10
kaplan-meier estimate (10) 10
research (10) 10
haploidentical (9) 9
lymphomas (9) 9
outcomes (9) 9
relapse (9) 9
remission induction (9) 9
surgical procedures, operative (9) 9
aml (8) 8
cyclophosphamide - therapeutic use (8) 8
graft vs host disease - etiology (8) 8
high-risk (8) 8
immunotherapy (8) 8
t cells (8) 8
time factors (8) 8
transplantation conditioning (8) 8
unrelated donors (8) 8
allogeneic (7) 7
allogeneic transplantation (7) 7
follow-up studies (7) 7
graft vs host disease - mortality (7) 7
hematologic neoplasms - mortality (7) 7
hemopoiesis (7) 7
leukemia, myeloid, acute - therapy (7) 7
medical colleges (7) 7
multiple myeloma - therapy (7) 7
risk factors (7) 7
stem cell transplantation (7) 7
usage (7) 7
abridged index medicus (6) 6
child (6) 6
cyclophosphamide - administration & dosage (6) 6
grafts (6) 6
histocompatibility testing (6) 6
immunosuppressive agents - therapeutic use (6) 6
leukemia, myeloid, acute - mortality (6) 6
medical research (6) 6
medicine, experimental (6) 6
non-hodgkins-lymphoma (6) 6
oncology, experimental (6) 6
patient outcomes (6) 6
peripheral-blood (6) 6
precursor cell lymphoblastic leukemia-lymphoma - therapy (6) 6
proportional hazards models (6) 6
rituximab (6) 6
siblings (6) 6
acute disease (5) 5
acute myelogenous leukemia (5) 5
adults (5) 5
antineoplastic agents - therapeutic use (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. 100 questions & answers about myeloma
by Bashey, Asad, 1960 and Abonour, Rafat and Huston, James W
2009, 2nd ed., ISBN 0763757071, vi, 144
Multiple myeloma
Book
Details down arrow
2. Non-myeloablative allogeneic transplantation
by Bashey, Asad, 1960 and Ball, Edward D. 1950- (Edward David)
2002, Cancer treatment and research, ISBN 0792376463, Volume 110, x, 216
Immunotherapy | Hematopoietic Stem Cell Transplantation | Transplantation | Transplantation Conditioning | Hematopoietic stem cells | Transplantation, Homologous | Cancer
Book
Details down arrow
3. Full Text T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
by Asad Bashey and Xu Zhang and Connie A. Sizemore and Karen Manion and Stacey Brown and H. Kent Holland and Lawrence E. Morris and Scott R. Solomon
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 10, pp. 1310 - 1316
Purpose T-cell-replete grafts from haploidentical donors using post-transplantation cyclophosphamide may represent a solution for patients who require... 
ACUTE-LEUKEMIA | TRIALS | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | HIGH-RISK | PERIPHERAL-BLOOD | ADJUSTED SURVIVAL CURVES | Hematologic Neoplasms - therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Blood Donors | Postoperative Care | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Unrelated Donors | Graft vs Host Disease - etiology | Siblings | Proportional Hazards Models | HLA Antigens - immunology | Cyclophosphamide - immunology | Disease-Free Survival | Outcome Assessment (Health Care) - statistics & numerical data | Immunosuppressive Agents - immunology | Graft vs Host Disease - prevention & control | T-Lymphocytes - immunology | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Peripheral Blood Stem Cells for T Cell–Replete Nonmyeloablative Hematopoietic Transplants Using Post-Transplant Cyclophosphamide
by Bashey, Asad
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 5, pp. 598 - 599
Hematology, Oncology and Palliative Medicine | SURVIVAL | ACUTE-LEUKEMIA | RELAPSE | BONE-MARROW-TRANSPLANTATION | HIGH-RISK | PHASE-II | DONORS | OUTCOMES | IMMUNOLOGY | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | TRANSPLANTATION | Antineoplastic Agents, Alkylating - therapeutic use | T-Lymphocytes - cytology | Humans | Graft vs Host Disease - prevention & control | T-Lymphocytes - immunology | Hematopoietic Stem Cell Mobilization | Lymphocyte Depletion | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Cyclophosphamide - therapeutic use | Graft vs Host Disease - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
by McCarthy, Philip L and Owzar, Kouros and Hofmeister, Craig C and Hurd, David D and Hassoun, Hani and Richardson, Paul G and Giralt, Sergio and Stadtmauer, Edward A and Weisdorf, Daniel J and Vij, Ravi and Moreb, Jan S and Callander, Natalie Scott and Van Besien, Koen and Gentile, Teresa and Isola, Luis and Maziarz, Richard T and Gabriel, Don A and Bashey, Asad and Landau, Heather and Martin, Thomas and Qazilbash, Muzaffar H and Levitan, Denise and McClune, Brian and Schlossman, Robert and Hars, Vera and Postiglione, John and Jiang, Chen and Bennett, Elizabeth and Barry, Susan and Bressler, Linda and Kelly, Michael and Seiler, Michele and Rosenbaum, Cara and Hari, Parameswaran and Pasquini, Marcelo C and Horowitz, Mary M and Shea, Thomas C and Devine, Steven M and Anderson, Kenneth C and Linker, Charles
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1770 - 1781
In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense... 
INTERGROUPE FRANCOPHONE | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | DEXAMETHASONE | PREDNISONE | RESPONSE CRITERIA | CONSOLIDATION THERAPY | IMPROVES SURVIVAL | THALIDOMIDE | BORTEZOMIB | LEUKEMIA | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Transplants & implants | Toxicity | Clinical trials | Stem cell transplantation | Cancer therapies | Cancer | Hemopoiesis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ipilimumab for Patients with Relapse after Allogeneic Transplantation
by Davids, Matthew S and Kim, Haesook T and Bachireddy, Pavan and Costello, Caitlin and Liguori, Rebecca and Savell, Alexandra and Lukez, Alexander P and Avigan, David and Chen, Yi-Bin and McSweeney, Peter and LeBoeuf, Nicole R and Rooney, Michael S and Bowden, Michaela and Zhou, Chensheng W and Granter, Scott R and Hornick, Jason L and Rodig, Scott J and Hirakawa, Masahiro and Severgnini, Mariano and Hodi, F. Stephen and Wu, Catherine J and Ho, Vincent T and Cutler, Corey and Koreth, John and Alyea, Edwin P and Antin, Joseph H and Armand, Philippe and Streicher, Howard and Ball, Edward D and Ritz, Jerome and Bashey, Asad and Soiffer, Robert J and Leukemia Lymphoma Soc Blood Canc R and Leukemia and Lymphoma Society Blood Cancer Research Partnership
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 2, pp. 143 - 153
Hematologic cancers that recur after allogeneic hematopoietic stem-cell transplantation are often difficult to treat. A small pilot study suggests that... 
MEDICINE, GENERAL & INTERNAL | PATTERN | CTLA-4 | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | BLOCKADE | HLA | VERSUS-HOST-DISEASE | HEMATOLOGIC MALIGNANCIES | T-CELLS | Hematologic Neoplasms - therapy | Recurrence | Myeloproliferative Disorders - therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Hematopoietic Stem Cell Transplantation | Leukemia - therapy | Antibodies, Monoclonal - therapeutic use | Induction Chemotherapy | Male | CD4 Lymphocyte Count | Hematologic Neoplasms - pathology | Transplantation, Homologous | Lymphoma - therapy | T-Lymphocytes, Regulatory | Adult | Female | Transplantation Immunology | Aged | Subpopulations | Graft-versus-host reaction | Immunoregulation | Myeloid leukemia | CD8 antigen | Body weight | Effector cells | Stem cell transplantation | Cytotoxicity | Lymphocytes T | Myelodysplastic syndrome | Hemopoiesis | Metastases | Cell activation | Immune checkpoint | Antitumor activity | Ligands | Lymphomas | Pharmaceutical industry | Acute myeloid leukemia | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older
by Bashey, Zain A and Zhang, Xu and Brown, Stacey and Jackson, Katelin and Morris, Lawrence E and Holland, H. Kent and Bashey, Asad and Solomon, Scott R and Solh, Melhem
Bone Marrow Transplantation, ISSN 0268-3369, 06/2018, Volume 53, Issue 6, pp. 756 - 763
Allografting from HLA-haploidentical donors (HID) is being increasingly utilized worldwide for patients lacking a conventional matched donor. However, its... 
DISEASE RISK INDEX | MYELODYSPLASTIC SYNDROME MDS | GRAFTS | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | 1ST COMPLETE REMISSION | TRANSPLANTATION | ONCOLOGY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ELDERLY-PATIENTS | HEMATOLOGIC MALIGNANCIES | BLOOD | Leukemia, Myeloid, Acute - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Cyclophosphamide - therapeutic use | Myelodysplastic Syndromes - therapy | Cyclophosphamide - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Female | Unrelated Donors | Aged | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Transplantation Conditioning - methods | Myelodysplastic Syndromes - pathology | Immunosuppressive Agents - pharmacology | Leukemia, Myeloid, Acute - therapy | Myelodysplastic Syndromes - drug therapy | Medical research | Cyclophosphamide | Usage | Analysis | Medicine, Experimental | Bone marrow | Transplantation | Research | Bone grafts | Graft-versus-host reaction | Transplants & implants | Health risks | Transplants | Gender | Survival | Patients | Direct reduced iron | Donors | Histocompatibility antigen HLA | Mud
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes
by Solh, MM and Dickhaus, E and Solomon, SR and Morris, LE and Zhang, X and Holland, HK and Bashey, A
BONE MARROW TRANSPLANTATION, ISSN 0268-3369, 11/2019, Volume 54, Issue 11, pp. 1756 - 1763
Fever is a common early complication after infusion of stem cells in patients undergoing T-replete HLA haploidentical transplantation using post-transplant... 
CYTOKINE-RELEASE SYNDROME | TOTAL-BODY IRRADIATION | SURVIVAL | BONE-MARROW | PERIPHERAL-BLOOD | SAFE | IMMUNOLOGY | 2-STEP APPROACH | TRANSPLANTATION | THERAPY | ONCOLOGY | DONOR TRANSPLANTATION | HEMATOLOGY | CD34 antigen | Graft-versus-host reaction | Transplants & implants | Mortality | Stem cell transplantation | Transplantation | Lymphocytes T | CD3 antigen | Regression analysis | Risk analysis | Morbidity | Fever | Hematopoietic stem cells | Risk factors | Hemopoiesis | Infusion | Cyclophosphamide | Grafts | Stem cells | Histocompatibility antigen HLA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies
by Solh, Melhem and Solomon, Scott R and Zhang, Xu and Holland, H. Kent and Morris, Lawrence E and Bashey, Asad
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3333 - 3333
HLA-haploidentical (haplo) stem cell transplantation is now widely used for patients lacking a suitably matched related or unrelated donor (MUD).... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy
by Solh, Melhem and Zhang, Xu and Bashey, Asad and Morris, Lawrence E and Holland, H. Kent and Solomon, Scott R
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4541 - 4541
Unmanipulated T-cell replete HLA-mismatched haploidentical transplantation (haplo) with post-transplant cyclophosphamide (PTCY) is now widely used for patients... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide
by Solh, Melhem and Solomon, Scott R and Holland, H. Kent and Morris, Lawrence E and Bashey, Asad
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4479 - 4479
Phase II trial evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
by Bashey, Asad and Zhang, Xu and Morris, Lawrence E and Holland, H. Kent and Solomon, Scott R and Solh, Melhem
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2014 - 2014
Relapse of leukemia (RL) is the most common cause of treatment failure following allogeneic hematopoietic cell transplantation (alloHCT) in patients with AML.... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
by Bashey, Asad and Zhang, Xu and Morris, Lawrence E and Holland, H. Kent and Solh, Melhem and Solomon, Scott R
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2006 - 2006
Severe (grade 3-4) acute GVHD (aGVHD) and NIH grade severe chronic GVHD (cGVHD) have historically been associated with poor survival. However, earlier... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
by Scott, Bart L and Pasquini, Marcelo C and Logan, Brent R and Wu, Juan and Devine, Steven M and Porter, David L and Maziarz, Richard T and Warlick, Erica D and Fernandez, Hugo F and Alyea, Edwin P and Hamadani, Mehdi and Bashey, Asad and Giralt, Sergio and Geller, Nancy L and Leifer, Eric and Le-Rademacher, Jennifer and Mendizabal, Adam M and Horowitz, Mary M and Deeg, H. Joachim and Horwitz, Mitchell E
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 11, pp. 1154 - 1161
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: A single center analysis of 389 consecutive patients
by Solh, Melhem M and Bashey, Asad and Solomon, Scott R and Morris, Lawrence E and Zhang, Xu and Brown, Stacey and Holland, H. Kent
Bone Marrow Transplantation, ISSN 0268-3369, 05/2018, Volume 53, Issue 5, pp. 576 - 583
Allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality especially in the first year after HCT. In this... 
RISK INDEX | COMPLETE REMISSION | UNRELATED DONORS | INTERNATIONAL BLOOD | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | MULTIVARIABLE ANALYSIS | SORAFENIB MAINTENANCE | ONCOLOGY | LATE DEATHS | WORKING GROUP-REPORT | HEMATOLOGY | Hematologic Neoplasms - therapy | Recurrence | Hematologic Neoplasms - mortality | Humans | Middle Aged | Risk Factors | Survivors | Male | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Infection - etiology | Transplantation, Homologous - mortality | Young Adult | Disease-Free Survival | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Aged | Tissue Donors | Graft vs Host Disease - etiology | Databases, Factual | Transplantation, Homologous - adverse effects | Graft-versus-host reaction | Transplants & implants | Mortality | Sex | Health risks | Risk reduction | Transplantation | Risk analysis | Patients | Survival | Morbidity | Risk factors | Hemopoiesis | Immunosuppression | Direct reduced iron | Mud
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease
by Solh, Melhem and Solomon, Scott R and Morris, Lawrence E and Holland, H. Kent and Zhang, Xu and Bashey, Asad
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 82 - 82
Abstract The fludarabine, high dose cytarabine and G_CSF with or without idarubicin combination regimen, referred to as FLAG+/-Ida, is commonly used as a... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Long-Term Follow-up of Myeloablative Haploidentical (HID) Peripheral Blood Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) Following Fludarabine and Total Body Irradiation (TBI)
by Solomon, Scott R and Zhang, Xu and Solh, Melhem and Morris, Lawrence E and Holland, H. Kent and Bashey, Asad
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3368 - 3368
Abstract Haploidentical donor (HID) transplant with post-transplant cyclophosphamide (PTCy) is being increasingly utilized worldwide. Although the original... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Extramedullary acute myelogenous leukemia
by Solh, Melhem and Solomon, Scott and Morris, Lawrence and Holland, Kent and Bashey, Asad
Blood Reviews, ISSN 0268-960X, 2016, Volume 30, Issue 5, pp. 333 - 339
Abstract Extramedullary leukemia (EM AML), also known as myeloid sarcoma, is a rare manifestation of acute myelogenous leukemia and often accompanies bone... 
Hematology, Oncology and Palliative Medicine | Myelogenous | Therapy | Leukemia | Extramedullary | Leukemia, Myeloid, Acute | Humans | Chemotherapy | Sarcoma | Stem cells | Bone marrow | Cytogenetics | Transplantation | Lymphomas | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Safety and efficacy of rituximab-based first line treatment of chronic GVHD
by Solomon, Scott R and Sizemore, Connie A and Ridgeway, Michelle and Zhang, Xu and Brown, Stacey and Holland, H. Kent and Morris, Lawrence E and Solh, Melhem and Bashey, Asad
Bone Marrow Transplantation, ISSN 0268-3369, 2018, Volume 54, Issue 8, pp. 1218 - 1226
Initial therapy of chronic GVHD (cGvHD) has not changed for over three decades, despite limited efficacy and long-term toxicity. We have previously shown in a... 
LONG-TERM SURVIVORS | BONE-MARROW | THROMBOTIC THROMBOCYTOPENIC PURPURA | IMMUNOLOGY | VERSUS-HOST-DISEASE | CONSENSUS DEVELOPMENT PROJECT | TRANSPLANTATION | ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | CLINICAL-TRIALS | DEPLETING THERAPY | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Corticoids | Graft-versus-host reaction | Therapy | Corticosteroids | Effectiveness | Toxicity | Feasibility studies | Rituximab | Safety
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
by Ciurea, Stefan O and Cao, Kai and Fernadez-Vina, Marcelo and Kongtim, Piyanuch and Malki, Monzr Al and Fuchs, Ephraim and Luznik, Leo and Huang, Xiao-Jun and Ciceri, Fabio and Locatelli, Franco and Aversa, Franco and Castagna, Luca and Bacigalupo, Andrea and Martelli, Massimo and Blaise, Didier and Handgretinger, Rupert and Roy, Denis-Claude and O'Donnell, Paul and Bashey, Asad and Lazarus, Hillard M and Ballen, Karen and Savani, Bipin N and Mohty, Mohamad and Nagler, Arnon
Bone Marrow Transplantation, ISSN 0268-3369, 05/2018, Volume 53, Issue 5, pp. 521 - 534
Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed.... 
STEM-CELLS | BONE-MARROW | CORD BLOOD | PERIPHERAL-BLOOD | PRIMARY GRAFT FAILURE | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | CROSS-MATCH | ONCOLOGY | HIGH-RISK | LEUKEMIA WORKING PARTY | HEMATOLOGY | T-CELLS | Humans | Isoantibodies - analysis | Hematopoietic Stem Cell Transplantation - adverse effects | Transplantation, Haploidentical - adverse effects | Bone Marrow Transplantation - adverse effects | HLA Antigens - immunology | Treatment Outcome | Graft Rejection - immunology | Tissue Donors | Viral antibodies | Usage | Analysis | Antibodies | Practice guidelines (Medicine) | Bone marrow | Transplantation | Research | Hematopoietic stem cells | Antigens | Cell survival | Transplants & implants | Progenitor cells | Blood | Hemopoiesis | Rejection | Isoimmunization | Offspring | Grafts | Histocompatibility antigen HLA | Females | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights